3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
20
OTHER_GOV
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
13
Glioblastoma
10
Glioma
7
Astrocytoma
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasms
4
Brain Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Stomach Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Melanoma
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Seroma
1
Rectal Neoplasms
1
Pleural Neoplasms
1
Pleural Effusion, Malignant
1
Pleural Effusion
1
Pleural Diseases
1
Patient Preference
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Inflammatory Breast Neoplasms
1
Interventions
pembrolizumab
97
Gemcitabine
70
Paclitaxel
58
Docetaxel
51
Carboplatin
48
Nivolumab
39
Cisplatin
39
Capecitabine
35
Pemetrexed
33
Fluorouracil
32
Bevacizumab
32
Cetuximab
31
130-nm albumin-bound paclitaxel
28
Trastuzumab
26
Albumin-Bound Paclitaxel
24
Irinotecan
23
Fulvestrant
22
Leucovorin
20
Oxaliplatin
18
Panitumumab
17
abemaciclib
16
Ipilimumab
16
cemiplimab
14
atezolizumab
14
Letrozole
14
Cyclophosphamide
14
palbociclib
12
Lapatinib
12
Drug Therapy
12
Doxorubicin
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasm Metastasis
×
Surgical Procedures, Operative
×
Clear all
NCT05081609
2026-02-24
IL Believe
Ascendis Pharma A/S
Phase 1/2
Active not recruiting
320 enrolled